Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
45.18 USD | +1.06% | -7.71% | -11.99% |
05:50pm | Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 | MT |
05:45pm | UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.99% | 90.6B | |
+26.27% | 653B | |
+27.00% | 556B | |
-6.76% | 354B | |
+20.82% | 331B | |
+1.82% | 296B | |
+13.09% | 233B | |
+5.46% | 201B | |
-9.61% | 193B | |
-6.12% | 144B |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- Bristol Myers Squibb : Combination Therapy Gets EMA Committee's Backing for Treating Gastric, Esophageal Cancers